In addition, we showed that HER2-targeted treatment was significantly less often applied in patients with HER2-positive BC and LM compared to patients with BM but without LM, while HER2-targeted therapy was associated with a significant improvement in survival. This evidence concerns the gene ERBB2 and breast cancer.